<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5845017</article-id><article-id pub-id-type="publisher-id">22485</article-id><article-id pub-id-type="doi">10.1038/s41598-018-22485-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Polygonumins A, a newly isolated compound from the stem of Polygonum minus Huds with potential medicinal activities</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>Rafidah</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sahidin</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1463-3090</contrib-id><name><surname>Taher</surname><given-names>Muhammad</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Low</surname><given-names>ChenFei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Noor</surname><given-names>Normah Mohd</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sillapachaiyaporn</surname><given-names>Chanin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chuchawankul</surname><given-names>Siriporn</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sarachana</surname><given-names>Tewarit</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tencomnao</surname><given-names>Tewin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Iskandar</surname><given-names>Faizah</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rajab</surname><given-names>Nor Fadilah</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Baharum</surname><given-names>Syarul Nataqain</given-names></name><address><email>nataqain@ukm.edu.my</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 1557</institution-id><institution-id institution-id-type="GRID">grid.412113.4</institution-id><institution>Institute of Systems Biology, </institution><institution>Universiti Kebangsaan Malaysia, </institution></institution-wrap>43600 Bangi, Selangor Malaysia </aff><aff id="Aff2"><label>2</label>Laboratory of Natural Products Chemistry, Faculty of Pharmacy, Universitas Halu Oleo, 93232 Kendari, Southeast Sulawesi Indonesia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0807 5654</institution-id><institution-id institution-id-type="GRID">grid.440422.4</institution-id><institution>Department of Pharmaceutical Technology, Kulliyah of Pharmacy, </institution><institution>International Islamic University of Malaysia, Jalan Istana, </institution></institution-wrap>25200 Kuantan, Pahang Malaysia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0244 7875</institution-id><institution-id institution-id-type="GRID">grid.7922.e</institution-id><institution>Department of Clinical Chemistry, Faculty of Allied Health Sciences, </institution><institution>Chulalongkorn University, </institution></institution-wrap>Bangkok, 10330 Thailand </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0244 7875</institution-id><institution-id institution-id-type="GRID">grid.7922.e</institution-id><institution>Department of Transfusion Medicine and Clinical Microbiology, Faculty of Allied Health Sciences, </institution><institution>Chulalongkorn University, </institution></institution-wrap>Bangkok, 10330 Thailand </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 1557</institution-id><institution-id institution-id-type="GRID">grid.412113.4</institution-id><institution>Biocompatibility Laboratory, Centre for Research and Instrumentation Management (CRIM), </institution><institution>Universiti Kebangsaan Malaysia, </institution></institution-wrap>43600 Bangi, Selangor Malaysia </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>8</volume><elocation-id>4202</elocation-id><history><date date-type="received"><day>23</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Polygonumins A, a new compound, was isolated from the stem of <italic>Polygonum minus</italic>. Based on NMR results, the compound&#x02019;s structure is identical to that of vanicoside A, comprising four phenylpropanoid ester units and a sucrose unit. The structure differences were located at C-3&#x02033;&#x02033;&#x02032;. The cytotoxic activity of polygonumins A was evaluated on several cancer cell lines by a cell viability assay using tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The compound showed the highest antiproliferative (p&#x02009;&#x0003c;&#x02009;0.05) activities against K562 (Human Leukaemia Cell Line), MCF7 (Human breast adenocarcinoma cell line), and HCT116 (Colorectal cancer cells) cells. Cytotoxic studies against V79&#x02013;4 cells were carried out and showed that polygonumins A was toxic at 50&#x02009;&#x000b5;g/ml, suggesting that this compound may be used as an anticancer drug without affecting normal cells. Polygonumins A also showed promising activity as an HIV-1 protease inhibitor with 56% relative inhibition. Molecular docking results indicated that the compound possesses high binding affinity towards the HIV protease over the low binding free energy range of -10.5 to -11.3&#x02009;kcal/mol. <italic>P</italic>. <italic>minus</italic> is used in Malaysian traditional medicine for the treatment of tumour cells. This is the first report on the use of <italic>P</italic>. <italic>minus</italic> as an HIV-1 protease inhibitor.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">The use of traditional herbal medicine is widespread, and plants are sources of many natural antioxidants that might serve as leads for the development of novel drugs. Natural antioxidants and bioactive compounds derived from traditional herbal medicines have received increasing attention for their potential use in treating certain human diseases. For example, traditional herbal medicine has been used widely in cancer patients<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> and to treat neurodegenerative disorders<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.</p><p id="Par3"><italic>Polygonum minus</italic>, also known as <italic>kesum</italic>, is an aromatic plant in the Polygonaceae family, which primarily grows in temperate regions. The plant originates from Southeast Asian countries such as Malaysia, Thailand, Vietnam, and Indonesia, where it is widely used as a spice and flavouring agent in the food industry. <italic>P</italic>. <italic>minus</italic> is abundant in Malaysia, where it has recently been listed in the National Agro-Food Policy by the Malaysian government to promote its production as a way to boost the agricultural economy. <italic>P</italic>. <italic>minus</italic> has also been recognized by the Malaysian government in the Herbal Product Blueprint as an essential oil-producing crop<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. <italic>Kesum</italic> oil is a source of natural aliphatic aldehydes and could be commercially produced in North East Victoria and Australia<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. In Japan, China, and Europe, <italic>kesum</italic> has long been used as a hot spice. The sprouts of <italic>kesum</italic> are a traditional vegetable in Japan and are often used in &#x02018;sashimi&#x02019;<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par4">In addition to its use as a spice in the food industry, <italic>P</italic>. <italic>minus</italic> has been reported for its use as a herbal medicine. <italic>Kesum</italic> leaf decoctions are traditionally used in indigestion relief, as ingredients in shampoo to remove dandruff<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, and as postnatal tonics<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. <italic>P</italic>. <italic>minus</italic> has been reported to exhibit anti-microbial activity<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, anti-inflammatory activity<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> and cytotoxic activity against HeLa (human cervical carcinoma) cells<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and gastric cytoprotective activity<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. <italic>P</italic>. <italic>minus</italic> has also been reported to be a source of natural antioxidants for its high total phenolic content and reducing capacity<sup><xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref></sup>. The pharmacological properties of <italic>P</italic>. <italic>minus</italic> are based on its chemical constituents. Therefore, numerous studies on the profiling of metabolites have been performed on <italic>P</italic>. <italic>minus</italic> in the search for its active compounds<sup><xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par5">Encouraged by the aforementioned findings, we aimed to isolate novel bioactive compounds from <italic>kesum</italic> in our continued investigations on <italic>kesum</italic> as a medicinal plant. In the present study, we isolated a new polyoxygenated aromatic compound (polygonumins A<bold>)</bold> from the stem of <italic>kesum</italic>. Polygonumins A demonstrated cytotoxic activities against several cancer cell lines, which indicated that it has potential value in the treatment of cancers such as leukaemia. These data provide baseline information for possible use in controlling cancer diseases, particularly leukaemia. In addition, the present study was undertaken to evaluate the antioxidant and anticholinesterase activities of <italic>P</italic>. <italic>minus</italic>. We also examined the potential of polygonumins A to serve as an HIV-1 protease inhibitor. Finally, a molecular docking study was performed to support our findings, which could lead to a new drug discovery in the near future.</p></sec><sec id="Sec2" sec-type="results"><title>Results and Discussion</title><sec id="Sec3"><title>Polygonumins A structure</title><p id="Par6">Spectroscopy data indicated that polygonumins A has a molecular formula of C<sub>52</sub>H<sub>50</sub>O<sub>21</sub>, as supported by HRESIMS [M&#x02009;+&#x02009;Na]<sup>+</sup> at <italic>m/z</italic> 1033.2697 (1033.9642 ([M&#x02009;+&#x02009;Na]<sup>+</sup> calc.) or [M]<sup>+</sup> at <italic>m/z</italic> 1010.2697 (1010.9642 ([M]<sup>+</sup> calc.).</p><p id="Par7">FTIR spectra showed absorption bands at (cm<sup>&#x02212;1</sup>) 3334.8 (hydroxyl); 2953.3 (C-H aliphatic); 1704 (C-carbonyl) and 1629.4; 1605.3, and 1513.7 (aromatics rings). <sup>1</sup>H NMR spectra (acetone<italic>d</italic><sub>6</sub>, 600&#x02009;MHz) &#x003b4;<sub>H</sub> (ppm) 4.21 (m, 1&#x02009;H, H-1a); 4.41 (m, 1&#x02009;H, H-1b); 5.62 (d, 7.8, 1&#x02009;H, H-3); 4.83 (ddd, 13.2, 10.2, 3.6, 1&#x02009;H, H-4); 4.31 (m, 1&#x02009;H, H-5); 4.61 (dd, 12.0, 3.0, 1&#x02009;H, H-6a); 4.47 (m, 1&#x02009;H, H-6b); 5.77 (d, 3.6, 1&#x02009;H, H-1&#x02032;); 4.67 (t, 7.8, 1&#x02009;H, H-2&#x02032;); 4.47 (m, 1&#x02009;H, H-3&#x02032;); 4.98 (t, 10.2, 1&#x02009;H, H-4&#x02032;); 4.11 (br t, 9.6, 1&#x02009;H, H-5&#x02032;); 4.41 (m, 1&#x02009;H, H-6&#x02032;a); 4.21 (m, 1&#x02009;H, H-6&#x02032;b); 7.55 (d, 8.4, 1&#x02009;H, H-2&#x02033;); 6.94 (d, 8.4, 1&#x02009;H, H-3&#x02033;); 6.94 (d, 8.4, 1&#x02009;H, H-5&#x02033;); 7.55 (d, 8.4, 1&#x02009;H, H-6&#x02033;); 7.57 (d, 8.4, 2&#x02009;H, H-2&#x02033;&#x02032;/6&#x02032;&#x02033;); 7.57 (d, 8.4, 2&#x02009;H, H-2&#x0201d;&#x02033;/6&#x02033;&#x02033;); 7.55 (d, 8.4, 2&#x02009;H, H-2&#x02033;&#x02033;&#x02032;/6&#x02033;&#x02033;&#x02032;); 6.90 (m, 2&#x02009;H, H-3&#x02033;&#x02032;/5&#x02033;&#x02032;); 6.90 (m, 2&#x02009;H, H-3&#x02033;&#x02033;/5&#x02033;&#x02033;), 6.94 (d, 8.4, 2&#x02009;H, H3&#x02033;&#x02033;&#x02032;/5&#x02033;&#x02033;&#x02032;); 7.78 (d, 15.6, 1&#x02009;H, H-7&#x02033;); 7.72 (d, 15.6, 1&#x02009;H, H-7&#x02033;&#x02032;); 7.68 (d, 10.2, 1&#x02009;H, H-7&#x02033;&#x02033;); 7.64 (dd, 13.2, 1.2, 1&#x02009;H, H-7&#x02033;&#x02033;&#x02032;); 6.51 (d, 14.4, 1&#x02009;H, H-8&#x02033;); 6.48 (d, 13.8, 1&#x02009;H; H-8&#x02033;&#x02032;); 6.43 (d, 12.6, 1&#x02009;H, H-8&#x02033;&#x02033;); 6.42 (d, 16.2, 1&#x02009;H, H-8&#x02033;&#x02033;&#x02032;). <sup>13</sup>C NMR spectra (acetone<italic>d</italic><sub>6</sub>, 125&#x02009;MHz) &#x003b4;<sub>C</sub> (ppm) 65.0 (C-1); 102.7 (C-2); 78.2 (C-3); 72.7 (C-4); 80.4 (C-5); 64.2 (C-6); 89.1 (C-1&#x02032;); 73.2 (C-2&#x02032;); 68.6 (C-3&#x02032;); 71.4 (C-4&#x02032;); 68.8 (C-5&#x02032;); 63.1 (C-6&#x02032;); 126.1(C-1&#x02033;); 130.21 (C-2&#x02033;); 115.9 (C-3&#x02033;); 159.81 (C-4&#x02033;); 115.9 (C-5&#x02033;); 130.21 (C-6&#x02033;); 130.24(C-2&#x02033;&#x02032;/6&#x02033;&#x02032;); 130.3(C-2&#x02033;&#x02033;/6&#x02033;&#x02033;); 130.4(C-2&#x02033;&#x02033;&#x02032;/6&#x02033;&#x02033;&#x02032;); 115.8 (3&#x02033;&#x02032;/5&#x02033;&#x02032;); 115.9 (3&#x02033;&#x02033;/5&#x02033;&#x02033;); 116.0 (3&#x02033;&#x02033;&#x02032;/5&#x02033;&#x02033;&#x02032;); 159.84 (C-4&#x0201c;&#x02032;); 159.9 (C-4&#x02033;&#x02033;); 160.2 (C-4&#x02033;&#x02033;&#x02032;); 169.6 (C=O<sup>1</sup>); 170.1 (C=O<sup>2</sup>); 20.0 (C-methyl<sup>1</sup>) and 20.1 (C-methyl<sup>2</sup>).</p><p id="Par8">According to HRESIMS data, polygonumins A has a molecular weight of <italic>m/z</italic> 1010.2697 and a molecular formula of C<sub>52</sub>H<sub>50</sub>O<sub>21</sub>. FTIR spectra indicated that the compound has various functional groups i.e., hydroxyl absorbance at 3334.8&#x02009;cm<sup>&#x02212;1</sup>, aliphatic carbon absorbance at 2953.3&#x02009;cm<sup>&#x02212;1</sup>, carbonyl absorbance at 1704 cm<sup>&#x02212;1</sup> and aromatic absorbance at 1629.4, 1605.3, and 1513.7&#x02009;cm<sup>&#x02212;1</sup>. The results are supported by NMR data (<sup>1</sup>H and <sup>13</sup>C NMR), which showed that the structure of polygonumins A comprises four phenylpropanoid units and a sucrose unit, which could be well distinguished from the structure of vanicoside A. NMR data for vanicoside A and polygonumins A are compared in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of NMR data (<sup>1</sup>H and <sup>13</sup>C) between vanicoside A and polygonumins A.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">C</th><th colspan="2">Vanicoside A*</th><th colspan="2">Polygonumins A</th></tr><tr><th><sup>1</sup>H (300&#x02009;MHz)</th><th><sup>13</sup>C (75&#x02009;MHz)</th><th><sup>1</sup>H (600&#x02009;MHz)</th><th><sup>13</sup>C (125&#x02009;MHz)</th></tr></thead><tbody><tr><td>1</td><td>4.25, 4.6&#x02009;m</td><td>63.80</td><td>4.21 (m, 1&#x02009;H),<break/>4.41 (m, 1&#x02009;H)</td><td>65.0</td></tr><tr><td>2</td><td>&#x02014;</td><td>102.12</td><td>&#x02014;</td><td>102.7</td></tr><tr><td>3</td><td>5.61 d (8.4)</td><td>77.64</td><td>5.62 (d, 7.8, 1&#x02009;H)</td><td>78.2</td></tr><tr><td>4</td><td>4.65&#x02009;m</td><td>72.65</td><td>4.83 (ddd, 13.2, 10.2, 3.6, 1&#x02009;H)</td><td>72.7</td></tr><tr><td>5</td><td>4.3&#x02009;m</td><td>79.82</td><td>4.31 (m, 1&#x02009;H)</td><td>80.4</td></tr><tr><td>6</td><td>4.6&#x02009;m</td><td>64.55</td><td>4.61 (dd, 12.0, 3.0, 1&#x02009;H), 4.47 (m, 1&#x02009;H)</td><td>64.2</td></tr><tr><td>1&#x02032;</td><td>5.66 d (3.6)</td><td>89.18</td><td>5.77 (d, 3.6, 1&#x02009;H)</td><td>89.1</td></tr><tr><td>2&#x02032;</td><td>4.69&#x02009;m</td><td>73.01</td><td>4.67 (t, 7.8, 1&#x02009;H)</td><td>73.2</td></tr><tr><td>3&#x02032;</td><td>3.9&#x02009;m</td><td>70.79</td><td>4.47 (m, 1&#x02009;H)</td><td>68.6</td></tr><tr><td>4&#x02032;</td><td>3.51 dd (9.4, 9.4)</td><td>70.66</td><td>4.98 (t, 10.2, 1&#x02009;H)</td><td>71.4</td></tr><tr><td>5&#x02032;</td><td>4.3&#x02009;m</td><td>70.79</td><td>4.11 (br t, 9.6, 1&#x02009;H)</td><td>68.8</td></tr><tr><td>6&#x02032;</td><td>4.3, 4.35&#x02009;m</td><td>64.49</td><td>4.41 (m, 1&#x02009;H), 4.21 (m, 1&#x02009;H)</td><td>63.1</td></tr><tr><td rowspan="4">1&#x02033;, 1&#x02033;&#x02032;</td><td>&#x02014;</td><td>125.69</td><td>&#x02014;</td><td>126.1</td></tr><tr><td>&#x02014;</td><td>125.77</td><td>&#x02014;</td><td>126.04</td></tr><tr><td>&#x02014;</td><td>125.84</td><td>&#x02014;</td><td>125.91</td></tr><tr><td>&#x02014;</td><td>126.38</td><td>&#x02014;</td><td>125.9</td></tr><tr><td>2&#x02033;</td><td>7.33 d (1.8)</td><td>110.08</td><td>7.55 (d, 8.4, 1&#x02009;H)</td><td>130.21</td></tr><tr><td>3&#x02033;</td><td>&#x02014;</td><td>148.97<sup>b</sup></td><td>6.94 (d, 8.4, 1&#x02009;H)</td><td>115.9</td></tr><tr><td>4&#x02033;</td><td>&#x02014;</td><td>147.62<sup>b</sup></td><td>&#x02014;</td><td>159.81</td></tr><tr><td>5&#x02033;</td><td>6.81</td><td>114.94</td><td>6.94 (d, 8.4, 1&#x02009;H)</td><td>115.9</td></tr><tr><td>6&#x02033;</td><td>7.11 dd (1.8, 8.2)</td><td>123.24</td><td>7.55 (d, 8.4, 1&#x02009;H)</td><td>130.21</td></tr><tr><td rowspan="4">7&#x02033;, 7&#x02032;&#x02033;&#x02033;</td><td rowspan="4">7.58, 7.62, 7.64, 7.72 ea d (16)</td><td/><td>7.78 (d, 15.6, 1&#x02009;H)</td><td>146.1</td></tr><tr><td>144.92</td><td>7.72 (d, 15.6, 1&#x02009;H)</td><td>145.3</td></tr><tr><td>145.91</td><td>7.68 (d, 10.2, 1&#x02009;H)</td><td>145.2</td></tr><tr><td>145.10</td><td>7.64 (dd, 13.2, 1.2, 1&#x02009;H)</td><td>145.1</td></tr><tr><td rowspan="4">8&#x02033;, 8&#x02032;&#x02033;&#x02033;</td><td rowspan="4">6.33, 6.40, 6.45, 6.53 ea d (16)</td><td>113.41</td><td>6.51 (d, 14.4, 1&#x02009;H)</td><td>113.6</td></tr><tr><td>113.87</td><td>6.48 (d, 13.8, 1&#x02009;H)</td><td>114.1</td></tr><tr><td>113.97</td><td>6.43 (d, 12.6, 1&#x02009;H)</td><td>114.2</td></tr><tr><td>114.53</td><td>6.42 (d, 16.2, 1&#x02009;H)</td><td>114.3</td></tr><tr><td rowspan="4">9&#x02033;, 9&#x02032;&#x02033;&#x02033;</td><td rowspan="4">&#x02014;</td><td>165.93</td><td>&#x02014;</td><td>166.0</td></tr><tr><td>165.96</td><td>&#x02014;</td><td>166.04</td></tr><tr><td>166.46</td><td>&#x02014;</td><td>166.5</td></tr><tr><td>166.64</td><td>&#x02014;</td><td>166.6</td></tr><tr><td rowspan="3">2/6&#x02032;&#x02033;&#x02212;2/6&#x02033;&#x02033;&#x02032;</td><td rowspan="3">7.45&#x02013;7.65&#x02009;m</td><td>130.02</td><td>7.57 (d, 8.4, 2&#x02009;H)</td><td>130.24</td></tr><tr><td>130.06</td><td>7.57 (d, 8.4, 2&#x02009;H)</td><td>130.3</td></tr><tr><td>130.31</td><td>7.55 (d, 8.4, 2&#x02009;H)</td><td>130.4</td></tr><tr><td rowspan="3">3/5&#x02033;&#x02032;&#x02212;3/5&#x02033;&#x02033;&#x02032;</td><td rowspan="3">6.85&#x02013;6.89&#x02009;m</td><td>115.63</td><td>6.90 (m, 2&#x02009;H)</td><td>115.8</td></tr><tr><td>115.64</td><td>6.90 (m, 2&#x02009;H)</td><td>115.9</td></tr><tr><td>115.73</td><td>6.94 (d, 8.4, 2&#x02009;H)</td><td>116.0</td></tr><tr><td rowspan="3">4&#x02032;&#x02033; &#x02212; 4&#x02033;&#x02033;&#x02032;</td><td rowspan="3">&#x02014;</td><td>159.53</td><td>&#x02014;</td><td>159.84</td></tr><tr><td>159.63</td><td>&#x02014;</td><td>159.9</td></tr><tr><td>159.81</td><td>&#x02014;</td><td>160.2</td></tr><tr><td>1&#x02033;&#x02033;&#x02033; (C=O)</td><td>&#x02014;</td><td>170.12 (1)</td><td>&#x02014;</td><td>170.1 (1)</td></tr><tr><td>2&#x02033;&#x02033;&#x02033;</td><td>2.06&#x02009;s</td><td>20.03 (1)</td><td>1.99 (s, 3&#x02009;H)</td><td>20.0 (1)</td></tr><tr><td>1&#x02033;&#x02033;&#x02033;&#x02032;</td><td rowspan="2">3.85&#x02009;s</td><td rowspan="4">55.25</td><td>&#x02014;</td><td>169.6 (2)</td></tr><tr><td rowspan="3">2&#x02033;&#x02033;&#x02033;&#x02032;</td><td>1.99 (s, 3&#x02009;H)</td><td rowspan="3">20.1 (1)</td></tr><tr><td rowspan="2">7.33 d (1.8, OH phenolic)</td><td>7.83, 7.64 (4 OH phenolic)</td></tr><tr><td>4.21<break/>4.41 2 (OH glucose)</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>Structure of (<bold>a</bold>) polygonumins A (<bold>b</bold>) vanicoside A.</p></caption><graphic xlink:href="41598_2018_22485_Fig1_HTML" id="d29e1334"/></fig></p><p id="Par9">Vanicoside A has a molecular formula of C<sub>51</sub>H<sub>50</sub>O<sub>21</sub> and a molecular weight of 998 mass units<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The structural differences between vanicoside A and polygonumins A are located at C-3&#x02033;&#x02033;&#x02032;. Carbon C-3&#x02033;&#x02033;&#x02032; of vanicoside A binds a methoxyl unit with &#x003b4;<sub>C</sub> and &#x003b4;<sub>H</sub> chemical shifts of 55.25 ppm and 3.85 ppm, respectively. Carbon C-3&#x02033;&#x02033;&#x02032; of polygonumins A binds a proton unit with a chemical shift &#x003b4;<sub>H</sub> of 6.94 (<italic>d</italic>, 8.4, 1&#x02009;H). Furthermore, structural differences between vanicoside A and polygonumins A are observed for the substituents at C-4, C-2&#x02032; and C-4&#x02032;. In vanicoside A, the substituents at C-4, C-2&#x02032; and C-4&#x02032; are hydroxyl, ethanoyl and hydroxyl units, respectively. However, the substituents at C-4, C-2&#x02032; and C-4&#x02032; in polygonumins A are ethanoyl, hydroxyl, and ethanoyl units, respectively. In the HMBC spectrum of polygonumins A in particular, the first ethanoyl unit shows long-range <sup>1</sup>H-<sup>13</sup>C correlations between the signal &#x003b4;<sub>H</sub> 4.98 ppm (H-4&#x02032;) and the carbonyl signal &#x003b4;<sub>C</sub> 170.1 ppm (C-2&#x02032;&#x02033;&#x02033;&#x02033;) and between the signal &#x003b4;<sub>H</sub> 1.99 ppm (H-1&#x02033;&#x02033;&#x02033;&#x02032;) and the carbonyl signal &#x003b4;<sub>C</sub> 170.1 ppm (C-2&#x02032;&#x02033;&#x02033;&#x02033;). The second ethanoyl unit of polygonumins A shows long-range <sup>1</sup>H-<sup>13</sup>C correlations between the signal &#x003b4;<sub>H</sub> 4.83 ppm (H-4) and the carbonyl signal &#x003b4;<sub>C</sub> 169.6 ppm (C-2&#x02033;&#x02033;&#x02033;) and between the signal &#x003b4;<sub>H</sub> 1.99 ppm (H-1&#x02033;&#x02033;&#x02033;&#x02032;) and the carbonyl signal &#x003b4;<sub>C</sub> 169.6 ppm (C-2&#x02033;&#x02033;&#x02033;) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>HMBC Polygonumins A.</p></caption><graphic xlink:href="41598_2018_22485_Fig2_HTML" id="d29e1412"/></fig></p></sec><sec id="Sec4"><title>Biological activities</title><p id="Par10">It has been recommended that in selecting plant medicines for cancer treatment, ethnopharmacological uses in cancer-relevant diseases such as inflammation, infection, and immune and skin disorders should be taken into account<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. In the present investigation, polygonumins A, a novel compound isolated from the stem of <italic>P</italic>. <italic>minus</italic>, was first evaluated for its antiproliferative activities against HCT116, C33A, H1299, MCF7, A549, and K-562 cancer cell lines using the MTT assay and then for its activities in radical scavenging and acetylcholinesterase inhibition. The activity towards HIV-1 protease inhibitor was also evaluated, as the newly isolated compound has a structure similar to that of vanicoside A.</p><p id="Par11">The IC<sub>50</sub> values inhibiting cell proliferation were determined, and the results are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The results showed that polygonumins A exhibited cytotoxicity against all tested cell lines except for the A549 cell line. Considering the cutoff point of 4&#x02009;&#x000b5;g/ml for potential anticancer compounds<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, values below this set point were obtained for this compound in HCT116 (IC<sub>50</sub> 3.24&#x02009;&#x000b5;g/ml), K562 (IC<sub>50</sub> 2.25&#x02009;&#x000b5;g/ml) and MCF7 (IC<sub>50</sub> 2.87&#x02009;&#x000b5;g/ml), indicating that polygonumins A could be defined as an anticancer compound. Polygonumins A was most effective against K562 (human leukaemia cell line), with an IC<sub>50</sub> of 2.25&#x02009;&#x000b5;g/ml, lower than that of doxorubicin (2.97&#x02009;&#x000b5;g/ml), highlighting the anti-leukaemia potential of polygonumins A. It has been well observed that leukaemia is more sensitive to chemotherapy than other malignancies are<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Biological activities of polygonumins A, vanicoside A and vanicoside B.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>PolygonuminsA</th><th/><th>Vanicoside A</th><th>Vanicoside B</th></tr></thead><tbody><tr><td>Biological activity</td><td/><td>IC<sub>50</sub> (&#x000b5;g/ml)<sup>a</sup></td><td/><td/></tr><tr><td rowspan="2">Cytotoxic activity</td><td rowspan="2">HCT116<break/>Doxorubicine<sup>b</sup><break/>C33A<break/>Doxorubicine<break/>H1299<break/>Doxorubicine<break/>MCF7<break/>Doxorubicine<break/>A549<break/>Doxorubicine<break/>K562<break/>Doxorubicine<break/>V79-4 cells</td><td rowspan="2">3.24 &#x000b1; 0.73<break/>2.97 &#x000b1; 0.17<break/>36.84 &#x000b1; 7.16*<break/>0.90 &#x000b1; 0.1<break/>4.71 &#x000b1; 0.68*<break/>10.12 &#x000b1; 0.35<break/>2.87 &#x000b1; 0.28*<break/>0.52 &#x000b1; 0.1<break/>&#x02014;<break/>3.13&#x000b1;0.11<break/>2.25 &#x000b1; 0.24<break/>2.13 &#x000b1; 0.54<break/>&#x0003e;50</td><td>&#x02014;</td><td>Inhibitory effects on two-stage carcinogenesis of mouse skin tumor<sup><xref ref-type="bibr" rid="CR48">48</xref></sup></td></tr><tr><td>Compound isolated from <italic>Polygonum pensylvanicum</italic> showed Cyototoxic activity againts MCF cell line<sup><xref ref-type="bibr" rid="CR18">18</xref></sup></td><td>Compound isolated from <italic>Polygonum pensylvanicum</italic> showed Cyototoxic activity againts MCF cell line<sup><xref ref-type="bibr" rid="CR18">18</xref></sup></td></tr><tr><td>Antioxidant Activity<break/>(DPPH scavenging activity)<break/>(Total Phenolic Content<break/>(mg GAE/g)<break/>(Reducing Power Assay (EC50 (&#x000b5;g/ml))</td><td>Polygonumins A<break/>Gallic acid<sup>b</sup><break/>Ascorbic acid<sup>b</sup><break/>Polygonumins A<break/>Polygonumins A<break/>Gallic acid</td><td>812.83 &#x000b1; 41.11*<break/>35.48 &#x000b1; 1.03<break/>63.12 &#x000b1; 1.11<break/>124.0625 &#x000b1;0.88<break/>89.3 &#x000b1; 2.3<break/>59.3 &#x000b1; 0.58</td><td>Isolation from <italic>Polygonum hydropiper</italic> showed significant DPPH scavenging activity at 26 &#x003bc;g/ml<sup><xref ref-type="bibr" rid="CR49">49</xref></sup><break/>&#x02014;</td><td>&#x02014;</td></tr><tr><td>Anticholinesterase activity</td><td>Polygonumins A<break/>Tacrine<sup>b</sup></td><td>1980 &#x000b1; 25.02*<break/>2.54 &#x000b1; 0.01</td><td>&#x02014;</td><td>Anticholinesterase activity at 90 &#x003bc;g/ml was reported in <italic>Polygonum sachalinensis</italic><sup><xref ref-type="bibr" rid="CR33">33</xref></sup></td></tr><tr><td>&#x003b1;-Glucosidase Inhibitory Activity</td><td>n.d</td><td/><td/><td>Inhibitory activity was observed at 225 &#x003bc;g/ml in <italic>Polygonum sachalinense</italic><sup><xref ref-type="bibr" rid="CR33">33</xref></sup></td></tr><tr><td>&#x003b2;-glucosidase Inhibitory activity</td><td>n.d</td><td/><td>IC 50 of 59.8 &#x003bc;g/ml was observed in <italic>Polygonum sachalinense</italic><sup><xref ref-type="bibr" rid="CR50">50</xref></sup></td><td>IC 50 of 48.3&#x000b1;1.39 was observed in <italic>Polygonum sachalinense</italic><sup><xref ref-type="bibr" rid="CR50">50</xref></sup></td></tr><tr><td>Antimicrobial activity</td><td>n.d</td><td/><td>Compound isolated from <italic>Polygonum sachalinense</italic> showed antimicrobial activity againts fish pathogen <italic>Photobacterium damselae</italic> subsp. <italic>piscicida</italic><sup><xref ref-type="bibr" rid="CR51">51</xref></sup></td><td>Isolated from <italic>Polygonum sachalinense</italic> showed antimicrobial activity againts fish pathogen <italic>Photobacterium damselae</italic> subsp. <italic>piscicida</italic><sup><xref ref-type="bibr" rid="CR51">51</xref></sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Data are expressed as mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments; <sup>b</sup>Positive control.</p><p>n.d not determined.</p><p>*Significant p&#x02009;&#x0003c;&#x02009;0.05 between positive control and tested compound.</p></table-wrap-foot></table-wrap></p><p id="Par12">In addition to its sensitivity towards the leukaemia cell line, polygonumins A exhibited cytotoxic activities against human breast cancer and colorectal cancer cells. This finding could well explain why polygonumins A has been widely used to treat digestive disorders. It is believed that the sugar moiety, a sucrose unit, in its structure plays an important role in determining its pharmacological and biological activities. Structure and activity relationship (SAR) analysis of several related compounds containing sugar moieties, such as CCL-34 and its natural analogues, revealed that the sugar moiety was essential to their anticancer activity<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. In particular, the sugar moiety was recognized to be critical to the topoisomerase inhibition activity of anthracyclines as antitumour drugs. It has also been suggested that the sugar structure in daunorubicin plays a critical role in determining its anticancer activity<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. To date, there is no report on the cytotoxicity activity of vanicoside A, except in an MCF cell line. However, vanicoside A has been classified as a member of the family of protein kinase C inhibitors<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, which exhibit antitumour effects.</p><p id="Par13">The equivalence between the therapeutic effect on cancer cell lines and the toxicological effect on target human organs is an important criterion of the applicability of an anticancer compound. Therefore, we conducted toxicological studies on the V79&#x02013;4 cell line (lung fibroblast cell line derived from Chinese hamsters) to determine the safe concentration range of polygonumins A. This test has been widely used to evaluate general cytotoxicity and target organ toxicity<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. In some cases, this test may also provide information about lethal dose <italic>in vivo</italic><sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. The results indicated a loss of viability of V79&#x02013;4 fibroblasts at concentrations above 50&#x02009;&#x000b5;g/ml following approximately 24&#x02009;hours of exposure. Thus, the compound is approximately 10 times as toxic towards cancer cells and normal cells at these concentrations, as it is at its therapeutic concentration.</p><p id="Par14">Interestingly, vanicoside A also showed significant &#x003b2;-glucosidase inhibitory activity, indicating promising therapeutic potential in the treatment of metastatic cancer and human immunodeficiency virus infection (HIV)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. As polygonumins A possesses a structure similar to that of vanicoside A, we performed an HIV-1 protease inhibition test against the newly isolated compound. Based on our results (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), polygonumins A showed potential activity as an HIV-1 protease inhibitor. A relative inhibition level of 56% towards HIV-1 protease was detected compared with pepstatin A as a positive control. This is the first report indicating that <italic>P</italic>. <italic>minus</italic> exhibits activity towards HIV-1 protease. Several <italic>Polygonum</italic> spp have been reported to possess anti-HIV properties, with compounds such as flavonoid glycoside, quercetin and phenolics playing an essential role in anti-HIV activity<sup><xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref></sup>. Based on the results of this study, we believe that the phenyl propanoid glycoside moiety in the structure of polygonumins A is associated with the activation of anti-HIV protease activity. Moreover, previous study have shown that the phenylpropanoid glycoside group acts as an inhibitor of HIV-1 integrase activity, thus supporting our findings<sup><xref ref-type="bibr" rid="CR31">31</xref></sup><table-wrap id="Tab3"><label>Table 3</label><caption><p>Relative inhibition of polygonumins A against HIV-1 protease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>% relative inhibition<sup>a</sup></th></tr></thead><tbody><tr><td>Pepstatin A (1&#x02009;mM)</td><td>81.48&#x02009;&#x000b1;&#x02009;0.76</td></tr><tr><td>1% DMSO</td><td>8.07&#x02009;&#x000b1;&#x02009;0.13</td></tr><tr><td>Polygonumins A</td><td>56.51&#x02009;&#x000b1;&#x02009;0.13</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Data are expressed as mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments.</p></table-wrap-foot></table-wrap></p><p id="Par15">Several techniques have been used to determine antioxidant capacity. One of the methods we used is based on scavenging activity, in which we measured the ability of polygonumins A to donate electrons to a free radical to scavenge potential damage. The antioxidant activity determined by the DPPH free radical-scavenging method (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) was not consistent with our expectations. The measured IC<sub>50</sub> value of 812&#x02009;&#x000b5;g/ml indicated that polygonumins A is far less potent than gallic acid and ascorbic acid. It has been reported that ethanolic, methanolic, and aqueous extracts of <italic>P</italic>. <italic>minus</italic> exhibit antioxidant activity as remarkable as that of gallic acid and ascorbic acid<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. This activity is due to the phenylpropane group of <italic>P</italic>. <italic>minus</italic>. The four units of the phenylpropanoid group in the structure have been show to produce lower scavenging activity<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. However, the high antioxidant activity of <italic>P</italic>. <italic>minus</italic> extracts has been attributed to high contents of polyphenolic compounds<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Therefore, we measured the total phenolic content of polygonumins A by the Folin-Ciocalteu method. Phenols consist of hydroxyl groups that are able to destroy free radicals to form stable phenoxyl radicals<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Although the results of the DPPH assay showed a weak scavenging ability, the total phenolic content of this compound is relatively high at 124.0625&#x02009;&#x000b1;&#x02009;0.88&#x02009;mg GAE/g when compared with that of crude extract. In our previous studies, we found that the total phenolic content in crude <italic>P</italic>. <italic>minus</italic> ethanolic extract produced the highest scavenging activity, ranging from 100 to 140&#x02009;mg GAE/g<sup>16</sup>. Perhaps the antioxidant activity of this compound is not due to DPPH scavenging activity alone. Because antioxidant activity can be realized by multiple mechanisms or a single mechanism, we analysed the reducing power capacity of polygonumins A. This assay determines a substance&#x02019;s ability to reduce Fe<sup>3+</sup> to Fe<sup>2+</sup>. The presence of antioxidants in the extracts result in the reduction of the ferric cyanide complex (Fe<sup>3+</sup>) to the ferrous cyanide form (Fe<sup>2+</sup>). We found that polygonumins A may act as an electron donor (a hydrogen electron donor), supporting its antioxidant activity, as the compound showed a comparatively high reducing capacity, with an EC<sub>50</sub> of 89.3&#x02009;&#x000b5;g/ml, near the value of its reference compound gallic acid (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The reducing power of this compound increased rapidly with its concentration. Based on this antioxidant activity, the compound&#x02019;s high total phenolic content was correlated with its reducing power. Hence, It can be inferred that polygonumins A could act as a strong antioxidant agent.</p><p id="Par16">It is well documented that the use of antioxidants may minimize neuronal degeneration and slow the progress of Alzheimer&#x02019;s disease<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Anticholinesterase activity in compounds has also been reported to be related to radical-scavenging activity<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Moreover, based on our previous findings on crude extracts of polygonumins A, the compound showed promising anticholinesterase activity<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Therefore, we evaluated the anticholinesterase activity of polygonumins A relative to that of tacrine. However, the compound showed only weak anticholinesterase activity at concentrations of up to 2&#x02009;mg/ml. (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), and the compound did not show potential to serve as an anticholinesterase drug. The IC<sub>50</sub> for this compound could not be determined due to its low activity; but we managed to determine the IC<sub>20</sub> value for this compound (1980 &#x000b5;g/ml).</p></sec><sec id="Sec5"><title>Molecular docking of polygonumins A, vanicoside A and pepstatin in HIV-1 protease (pdb ID: 3OXC)</title><p id="Par17">Polygonumins A appeared to possess high binding affinity towards HIV protease (pdb ID: 3OXC), as indicated by low binding free energy range of &#x02212;10.5 to &#x02212;11.3&#x02009;kcal/mol (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) recorded in 3 independent runs. The low binding free energies are comparable to those of vanicoside A (&#x02212;10.5 to &#x02212;11.7&#x02009;kcal/mol) docked to the same protein, as illustrated in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. Moreover, pepstatin (positive control) exhibited low binding free energies of &#x02212;8.9 to &#x02212;9.5&#x02009;kcal/mol in 3 independent runs. Pepstatin has been used as positive control drug that exhibits anti-HIV properties through enzymatic assay<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>, and thus, pepstatin was included as a reference in a comparative analysis of molecular docking to determine the compound&#x02019;s activity as an anti-HIV protease based on its potential binding affinity. The structures possessing the lowest binding free energy were visualized, and hydrogen bond analysis was conducted using the surface/binding analysis tool in UCSF Chimera version 1.11. The residues involved in hydrogen bond interactions are summarized in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. Moreover, superimposition of the structures showed that polygonumins A, vanicoside A and pepstatin were docked in a similar binding domain (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Affinity of polygonumins A, vanicoside A and pepstatin to HIV-1 protease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Affinity (kcal/mol)</th></tr><tr><th>run #1</th><th>run #2</th><th>run #3</th></tr></thead><tbody><tr><td>Polygonumins A</td><td>&#x02212;11.3</td><td>&#x02212;10.5</td><td>&#x02212;10.5</td></tr><tr><td>Vanicoside A</td><td>&#x02212;10.5</td><td>&#x02212;11.1</td><td>&#x02212;11.7</td></tr><tr><td>Pepstatin</td><td>&#x02212;9.5</td><td>&#x02212;9.4</td><td>&#x02212;8.9</td></tr></tbody></table></table-wrap><fig id="Fig3"><label>Figure 3</label><caption><p>Hydrogen bond interaction of polygonumins A (<bold>a</bold>), vanicoside A (<bold>b</bold>) and pepstatin (<bold>c</bold>) with HIV-1 protease at respective lower binding energy.</p></caption><graphic xlink:href="41598_2018_22485_Fig3_HTML" id="d29e2073"/></fig><table-wrap id="Tab5"><label>Table 5</label><caption><p>Residues of HIV-1 protease involved in hydrogen bond interactions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Residue</th><th>Position</th></tr></thead><tbody><tr><td>Polygonumins A</td><td>ASP<break/>GLY</td><td>29<break/>27</td></tr><tr><td>Vanicoside A</td><td>ASP<break/>LYS<break/>ILE<break/>ILE<break/>THR</td><td>30<break/>45<break/>50<break/>150<break/>180</td></tr><tr><td>Pepstatin</td><td>ASP<break/>ASP<break/>GLY<break/>GLY<break/>GLY</td><td>29<break/>129<break/>48<break/>127<break/>27</td></tr></tbody></table></table-wrap><fig id="Fig4"><label>Figure 4</label><caption><p>Superimposition of the structures revealed polygonumins A (red), vanicoside A (blue), and pepstatin (green) were docked in a similar binding domain.</p></caption><graphic xlink:href="41598_2018_22485_Fig4_HTML" id="d29e2169"/></fig></p><p id="Par18">Recent studies have reported the anti-HIV activity of several bioactive compounds derived from plant extracts<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup> and mushroom<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. The current study examined the anti-HIV activity of polygonumins A, and the compound&#x02019;s potential activity was further evaluated to identify the potential interactions of the compound with mutant HIV-1 proteases through molecular docking simulation. Mutant HIV-1 proteases available in the protein databank were downloaded and submitted to docking analysis using VinaAutodock. Polygonumins A was found to engage in potential interactions with mutant HIV-1 proteases with the following PDB IDs: 3PWM, 4HDB, 4HDF, 4HEG, and 4YHQ; the affinities recorded were lower than &#x02212;10 kcal/mol. The potential interaction was found to be particularly significant for the mutant 4YHQ, for which the affinity was as low as &#x02212;13.8&#x02009;kcal/mol. These results are comparable to those obtained for the positive control drug pepstatin, which showed a significant binding affinity towards the mutant HIV-1 proteases. The results are summarized in Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>. The docked positions of pepstatin and polygonumins A are depicted in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>. This analysis indicated that polygonumins A possesses the potential to inhibit a range of HIV-1 protease mutants that are currently known to resist available antiretroviral drugs. The potential anti-HIV activities against different protease mutants were predicted based on a complementary fit of polygonumins A with the target HIV protease mutants relative to the positive control drug pepstatin. This approach is well established for identifying potent HIV protease inhibitors<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, which can be used for drug development in the future.<table-wrap id="Tab6"><label>Table 6</label><caption><p>Affinities of polygonumins A and pepstatin docked in HIV-1 protease mutants. Residues of HIV-1 protease mutants involved in hydrogen bond interactions with polygonumins A and pepstatin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Protease Mutant (PDB ID)</th><th colspan="2">Affinity (kcal/mol)</th><th colspan="2">Residues involved in hydrogen bond interaction with ligand : hydrogen bond distance</th></tr><tr><th>Polygonumins A</th><th>Pepstatin</th><th>Polygonumins A</th><th>Pepstatin</th></tr></thead><tbody><tr><td>3KT5</td><td>&#x02212;7.3</td><td>&#x02212;8.5</td><td>ASP 1029: 3.038<break/>LYS 1045: 2.937<break/>ASP 1030: 3.459</td><td>ASP 29: 3.103<break/>GLY 1027: 3.315<break/>GLY 48: 3.244</td></tr><tr><td>3NU4</td><td>&#x02212;8.3</td><td>&#x02212;8.6</td><td>ASP 29: 3.346<break/>LYS 45: 2.912<break/>LYS 45: 3.176</td><td>ASP 29: 2.761<break/>GLY 27: 3.139<break/>GLY 27: 2.985<break/>GLY 127: 3.243</td></tr><tr><td>3NU5</td><td>&#x02212;9.1</td><td>&#x02212;8.3</td><td>LYS 145: 3.386<break/>LYS 145: 2.800<break/>GLY 148: 3.285<break/>GLU 21: 3.345</td><td>VAL 50: 3.225<break/>VAL 150: 3.171<break/>GLY 48: 2.972<break/>ASP 29: 2.859</td></tr><tr><td>3NU6</td><td>&#x02212;8.3</td><td>&#x02212;8.3</td><td>LYS 45: 3.126<break/>ARG 87: 3.111<break/>ARG 87: 3.039<break/>ARG 8: 2.982<break/>ARG 8: 3.257<break/>ARG 8: 3.335<break/>ARG 8: 3.211</td><td>ARG 8: 3.099<break/>ARG 8: 3.006<break/>ASP 29: 3.269<break/>GLY 27: 2.957<break/>GLY 48: 3.089<break/>GLY 27: 2.779</td></tr><tr><td>3NU9</td><td>&#x02212;9.3</td><td>&#x02212;8.3</td><td>ILE 50: 3.012<break/>GLU 121: 3.158<break/>ASP 130: 3.269<break/>PRO 181: 3.491</td><td>ASP 29: 3.087<break/>ILE 150: 3.024<break/>GLY 48: 3.195<break/>GLY 48: 3.166<break/>GLY 48: 2.920</td></tr><tr><td>3NUJ</td><td>&#x02212;8.6</td><td>&#x02212;8.1</td><td>ASP 30: 3.004<break/>LYS 45: 2.965<break/>ARG 8: 3.222<break/>ILE 50: 3.280<break/>MET 46: 3.620</td><td>ASP 29: 3.077<break/>GLY 48: 3.091<break/>ILE 50: 3.078<break/>ASP 30: 2.861<break/>GLY 48: 3.074<break/>GLY 48: 3.084<break/>ASP 25: 3.244</td></tr><tr><td>3NUO</td><td>&#x02212;9.3</td><td>&#x02212;8.6</td><td>ARG 8: 3.381<break/>ARG 8: 2.944</td><td>ASP 29: 2.965<break/>ILE 50: 3.063<break/>GLY 27: 3.018<break/>GLY 48: 3.276<break/>GLY 48: 2.780<break/>GLY 48: 2.892</td></tr><tr><td>3PWM</td><td>&#x02212;10.2</td><td>&#x02212;9.8</td><td>ASP 30: 2.895<break/>ILE 150: 3.098<break/>ASP 30: 3.371<break/>PRO 181: 3.317</td><td>ASP 29: 2.930<break/>GLY 48: 2.880<break/>GLY 48: 3.237<break/>ASP 29: 2.936</td></tr><tr><td>3S43</td><td>&#x02212;8.3</td><td>&#x02212;8.4</td><td>ARG 8: 2.807<break/>ASP 130: 2.982<break/>LYS 145: 3.279<break/>LYS 145: 3.094<break/>ARG 187: 2.994<break/>MET 146: 3.573</td><td>ILE 50: 3.285<break/>GLY 48: 3.113<break/>GLY 48: 3.271<break/>ASP 29: 2.817<break/>GLY 48: 3.283<break/>GLY 48: 2.794</td></tr><tr><td>3TH9</td><td>&#x02212;7.5</td><td>&#x02212;8.4</td><td>ARG 8: 2.937<break/>GLU 21: 3.160<break/>GLY 48: 3.249</td><td>ASP 29: 2.936<break/>ASP 30: 3.356<break/>ASP 29: 3.327<break/>GLY 48: 3.200</td></tr><tr><td>3VF5</td><td>&#x02212;9.5</td><td>&#x02212;9.7</td><td>ARG 8: 2.962<break/>ARG 8: 3.185<break/>GLY 48: 3.153</td><td>ASP 29: 2.991<break/>ASP 29: 3.370<break/>GLY 27: 3.066<break/>GLY 48: 2.894<break/>ASP 25: 3.097</td></tr><tr><td>3VFB</td><td>&#x02212;9.4</td><td>&#x02212;9.7</td><td>ASP 29: 2.917<break/>ASP 30: 3.371<break/>LYS 45: 2.939<break/>ASN 83: 3.022<break/>ASP 30: 3.335<break/>PRO 81: 3.522</td><td>ARG 8: 2.792<break/>ASP 30: 3.031<break/>GLY 27: 3.015<break/>GLY 27: 3.157<break/>ASP 25: 2.967<break/>GLY 48: 2.602<break/>ASP 25: 2.962<break/>ASP 25: 3.130</td></tr><tr><td>4GB2</td><td>&#x02212;7.5</td><td>&#x02212;8.3</td><td>LYS 45: 3.352<break/>LYS 45: 3.389<break/>ARG 87: 3.383<break/>ARG 87: 2.878<break/>THR 91: 3.220<break/>ASP 29: 3.216</td><td>LYS 45: 3.121<break/>GLY 48: 3.035<break/>ARG 8: 3.365<break/>ARG 8: 2.941<break/>GLY 27: 3.034<break/>GLY 48: 2.945<break/>GLY 27: 3.289</td></tr><tr><td>4HDB</td><td>&#x02212;11.4</td><td>&#x02212;11.2</td><td>ASP 129: 3.175<break/>ASN 130: 2.964<break/>ASN 130: 3.386<break/>LYS 145: 3.088<break/>ASN 130: 3.073</td><td>LYS 45: 3.400<break/>GLY 48: 3.100<break/>GLY 48: 3.110<break/>GLY 48: 2.802<break/>GLY 148: 3.261</td></tr><tr><td>4HDF</td><td>&#x02212;10.8</td><td>&#x02212;11.2</td><td>GLY 48: 3.356<break/>GLY 48: 3.298<break/>ARG 8: 3.335<break/>ARG 8: 3.296<break/>ASP 25: 3.295<break/>GLU 21: 3.436</td><td>GLY 27: 3.223<break/>GLY 48: 3.146<break/>GLY 27: 3.341<break/>ASP 25: 3.124<break/>GLY 48: 2.759<break/>ASP 25: 3.462<break/>GLY 48: 2.996<break/>GLY 48: 2.989<break/>ASP 30: 3.165</td></tr><tr><td>4HEG</td><td>&#x02212;11.4</td><td>&#x02212;11.3</td><td>GLY 48: 3.381<break/>GLY 48: 3.243<break/>ASP 30: 3.125<break/>GLY 49: 3.551</td><td>ASP 29: 2.882<break/>GLY 48: 3.135<break/>GLY 48: 3.037<break/>GLY 48: 3.141<break/>GLY 48: 3.166<break/>GLY 48: 3.175</td></tr><tr><td>4YHQ</td><td>&#x02212;13.8</td><td>&#x02212;12.2</td><td>ARG 8: 3.193<break/>ARG 8: 2.931<break/>VAL 82: 3.170<break/>ASP 29: 3.268<break/>ASN 30: 3.325<break/>ASN 30: 3.184<break/>LYS 45: 3.258<break/>LYS 45: 2.836<break/>GLY 48: 3.261<break/>GLY 48: 2.964<break/>ASN 30: 3.208<break/>ASN 30: 3.478<break/>ASN 30: 3.384</td><td>ASP 29: 2.803<break/>GLY 48: 3.098<break/>GLY 48: 2.935<break/>GLY 48: 2.955<break/>GLY 48: 3.178<break/>GLY 48: 2.946<break/>GLY 27: 2.629<break/>GLY 48: 3.292<break/>ASN 30: 2.953</td></tr></tbody></table></table-wrap><fig id="Fig5"><label>Figure 5</label><caption><p>polygonumins A (yellow chain), and pepstatin (red chain) docked in HIV-1 protease mutants (labelled with PDB ID).</p></caption><graphic xlink:href="41598_2018_22485_Fig5_HTML" id="d29e2810"/></fig></p></sec></sec><sec id="Sec6"><title>Experimental procedures</title><sec id="Sec7"><title>Plant material</title><p id="Par19">The stem of <italic>P</italic>. <italic>minus</italic> was originally collected from Ulu Yam, Malaysia, and a voucher specimen was deposited in the UKMB Herbarium, Universiti Kebangsaan Malaysia. Specimens were identified by a taxonomist and further confirmed by ITS sequencing<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Samples were washed and stored at &#x02212;80&#x02009;&#x000b0;C prior to use.</p></sec><sec id="Sec8"><title>Isolation of polygonumins A</title><p id="Par20">A total of 5&#x02009;kg of <italic>P</italic>. <italic>minus</italic> stem bark powder (230&#x02013;250 mesh) was extracted using methanol 3 times for 24&#x02009;hours each time at room temperature. The extracts were concentrated by a vacuum rotary evaporator at low pressure to yield a dark-green gum (260&#x02009;g). A total of 150&#x02009;g of methanol extract was fractionated by vacuum liquid chromatography (VLC) using a column (&#x003a6; 10&#x02009;cm) with silica gel 60PF<sub>254</sub> (0.063&#x02013;0.200&#x02009;mm) as an adsorbent and a chloroform:methanol mixture with increasing polarity (100% chloroform, 90&#x02013;10%, 80&#x02013;20%, and MeOH 100%) to yield 5 fractions i.e., F<sub>1</sub> (2.1&#x02009;g), F<sub>2</sub> (4.4&#x02009;g), F<sub>3</sub> (8.4&#x02009;g), F<sub>4</sub> (10.3&#x02009;g), and F<sub>5</sub> (88.3&#x02009;g), respectively. Based on the spot size produced by thin layer chromatography (TLC), F<sub>4</sub> was refractionated by the VLC method using a column (&#x003a6; 5&#x02009;cm) with silica gel 60PF<sub>254</sub> (0.063&#x02013;0.200&#x02009;mm) as an adsorbent and a chloroform:methanol mixture (100% chloroform, 90&#x02013;10%, 80&#x02013;20%, and MeOH 100%) as an eluent to produce 4 fractions: F<sub>41</sub> (0.8&#x02009;g), F<sub>42</sub> (1.3&#x02009;g), F<sub>43</sub> (1.8&#x02009;g) and F<sub>44</sub> (3.3&#x02009;g), respectively. The selected fractions, F<sub>43</sub> and F<sub>42</sub> (1.8&#x02009;g), were combined and further purified by radial chromatography (RC) with silica gel 60PF<sub>254</sub> containing gypsum as an adsorbent with a chloroform:methanol mixture as an eluent with increasing polarity (95:5% 100% MeOH) to yield Fraction 4232 (0.4&#x02009;g). Radial chromatography was then performed iteratively using the same eluent mixture to obtain polygonumins A (107&#x02009;mg) as a white amorphous compound with a melting point of 150.2&#x02013;152.0&#x02009;&#x000b0;C. The schematic representation of polygonumins A isolation is summarized in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>.<fig id="Fig6"><label>Figure 6</label><caption><p>Schematic representation of polygonumins A isolation.</p></caption><graphic xlink:href="41598_2018_22485_Fig6_HTML" id="d29e2899"/></fig></p></sec><sec id="Sec9"><title>Compound identification</title><p id="Par21">The structure of the purified compound was determined based on spectral data recorded on a Frontier Perkin-Elmer FTIR/NIR (Perkin-Elmer Inc., Norwalk, CT, USA) spectrophotometer and a Bruker NMR 600&#x02009;MHz Cryo-Probe instrument that could perform 1-D and 2-D NMR measurements (Bruker, Germany). ESIMSs were recorded on a Bruker Daltonics micrOTOF-Q 86 (direct infuse&#x02009;+&#x02009;ve.m). Isolation was carried out by radial chromatography using round glass plates on a Merck Kieselgel 60 PF<sub>254</sub> (art. no. 7749), and the profile was analysed using aluminium sheets measuring 20&#x02009;&#x000d7;&#x02009;20&#x02009;cm on a Merck TLC silica gel 60 F<sub>254</sub> with a thickness of 0.25&#x02009;mm (art. no. 5554) with UV light detection (254&#x02009;nm) or CeSO<sub>4</sub> spraying followed by heating.</p></sec><sec id="Sec10"><title>Anticholinesterase activity</title><p id="Par22">Inhibition of acetylcholinesterase (AChE) was assessed using the spectrophotometric method developed by Ellman<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> with slight modifications. Electric eel AchE (electric eel acetyl-cholinesterase, type-VI-S, EC 3.1.1.7, Sigma&#x02013;Aldrich, St. Louis, USA) and acetylthiocholine iodide (Sigma&#x02013;Aldrich, Steinheim, Germany) were used as the enzyme and substrate, respectively. Briefly, 125&#x02009;&#x003bc;l of DTNB (Sigma&#x02013;Aldrich, Steinheim, Germany) (50&#x02009;mM Tris-HCl, pH 8, 0.1&#x02009;M NaCl, 0.02&#x02009;M MgCl<sub>2</sub>.6H<sub>2</sub>O), 25&#x02009;&#x003bc;l of AChE (0.2 U/ml), 25&#x02009;&#x003bc;l of test compound solution in DMSO, and 50&#x02009;&#x003bc;l of buffer (50&#x02009;mM Tris-HCl, pH 8, 0.1% BSA) were mixed and incubated at 25&#x02009;&#x000b0;C for 30&#x02009;min. DMSO or buffer (25&#x02009;&#x003bc;l) was added instead of the test compound solution in control experiments. The reaction was then initiated by the addition of 25&#x02009;&#x003bc;l of acetylthiocholine iodide (0.25&#x02009;mmol/l), which brought the final volume to 250&#x02009;&#x003bc;l. The formation of 5-thio-2-nitrobenzoate anion from the enzymatic hydrolysis of acetylthiocholine iodide was monitored based on the absorbance at 412&#x02009;nm on a 96-well microplate reader (Model 680, Biorad Inc., and Hercules, CA, USA). The reaction rates were calculated from data collected at specific time points over the first 180&#x02009;s in 20&#x02009;s increments. Percent inhibition of AChE was determined by the ratio of the reaction rate with the test sample to that with the blank control (DMSO in Tris-HCl buffer, pH 8.0) using the formula (<italic>E</italic> &#x02212; <italic>S</italic>)/<italic>E</italic>&#x02009;&#x000d7;&#x02009;100, where <italic>E</italic> is the activity of enzyme with DMSO and <italic>S</italic> is the activity of enzyme with the test sample. The experiments were carried out in triplicate. Tacrine was used as a reference compound.</p></sec><sec id="Sec11"><title>Antioxidant activity</title><sec id="Sec12"><title>Free radical-scavenging assa<bold>y</bold></title><p id="Par23">Radical-scavenging activities were determined by the DPPH (2,2-diphenyl-1-picrylhydrazyl) assay. Various concentrations of the experimental samples were obtained, and the volume was adjusted to 200&#x02009;&#x003bc;l with ethanol. Approximately 100&#x02009;&#x003bc;l of 0.5&#x02009;mM DPPH in methanol was added to the samples or standard (ascorbic acid and gallic acid) in a 96-well plate. After incubation for 30&#x02009;min in the dark, changes in absorbance at 600&#x02009;nm were measured on a 96-well plate reader. IC<sub>50</sub> was calculated as the sample concentration required for a 50% decrease in the absorbance of a control solution of DPPH<sub>.</sub></p></sec><sec id="Sec13"><title>Reducing power assay</title><p id="Par24">Ferric reducing antioxidant power was determined by the direct reduction of Fe<sup>3+</sup> (CN<sup>&#x02212;</sup>)<sub>6</sub> to Fe<sup>2+</sup> (CN<sup>&#x02212;</sup>)<sub>6</sub> and by measuring the absorbance resulting from the formation of the Perls&#x02019; Prussian Blue complex following the addition of excess ferric ions (Fe<sup>3+</sup>). The reducing power method was performed as reported by Oyaizu<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> with slight modifications. Different concentrations of samples (50&#x02009;&#x000b5;g/ml to 500&#x02009;&#x000b5;g/ml) were mixed with 2&#x02009;ml of 0.2&#x02009;M, pH 6.6 sodium phosphate buffer and 1.25&#x02009;ml of potassium ferricyanide. The mixture was incubated at 50&#x02009;&#x000b0;C for 20&#x02009;minutes. After 20&#x02009;minutes of incubation, 1.25&#x02009;ml of trichlorocetic acid (10%) was added. Finally, 0.5&#x02009;ml of FeCl<sub>3 (0.1%)</sub> was added to the mixture and incubated for 10&#x02009;minutes. The intensity of the blue-green colour was measured at 700&#x02009;nm. Increases in the absorbance of the reaction mixture indicated an increase in the reduction capability. The EC<sub>50</sub> value (&#x000b5;g/mL) associated with the reducing power-the extract concentration at which the absorbance was 0.5 was calculated from a graph of absorbance at 700&#x02009;nm against the extract concentration. Gallic acid was used as a positive control.</p></sec><sec id="Sec14"><title>Total phenolic content</title><p id="Par25">The total phenolic content was determined using the Folin-Ciocalteu method<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. The reaction mixture was prepared by mixing 0.2&#x02009;ml of sample (1&#x02009;mg/mL) and 1.5&#x02009;ml of 10% Folin-Ciocalteu reagent dissolved in water. The mixture was allowed to equilibrate for 5&#x02009;minutes and then mixed with 1.5&#x02009;ml 7.5% Na<sub>2</sub>CO<sub>3</sub> solution. After incubation for 60&#x02009;minutes at room temperature in the dark, the absorbance of the mixture was read at 725&#x02009;nm against a blank using a spectrophotometer. The blank was prepared by using DMSO instead of a sample. The sample procedure was repeated for gallic acid at different concentrations, i.e., 0.00, 0.25, 0.50, 0.75 and 1&#x02009;mg; the results were used to produce a calibration curve. Total phenolic content was calculated as the milligrams of gallic acid equivalent (GAE) per gram of sample (mg GAE/g) by using the gallic acid calibration curve, y&#x02009;=&#x02009;0.0016&#x000d7;&#x02009;+&#x02009;0.0295, R&#x000b2;&#x02009;=&#x02009;0.9548.</p></sec></sec><sec id="Sec15"><title><italic>In vitro</italic> cytotoxicity</title><sec id="Sec16"><title>Cell lines and cell culture</title><p id="Par26">Cells of the lines K-562 (human leukaemia cell line), C33A (cervical cancer cell line), HCT116 (colorectal cancer cell line), and A549 (human lung adenocarcinoma epithelial cell line) were purchased from the American Type Culture Collection. H1299 (human non-small cell lung cancer cell line) and MCF7 (human breast adenocarcinoma cell line) were provided as a courtesy by Prof. Masa-Ikeda of Tokyo Medical and Dental University. Cells were cultured in DMEM media supplemented with 10% foetal bovine serum (FBS) and 1% penicillin and streptomycin. All cell lines were cultured at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub>.</p></sec><sec id="Sec17"><title>V79 fibroblast cultures</title><p id="Par27">V79&#x02013;4 cells were grown in tissue culture flasks using DMEM as the growth medium at 37&#x02009;&#x000b0;C in a humidified atmosphere of 5% carbon dioxide and 95% air. Cultures were examined daily to ensure they remained healthy. The confluent monolayer was removed by trypsinization, and the number of viable cells was calculated. Cells were seeded into a 96-well plate at a seeding density of 10 000 cells/well and incubated at 37&#x02009;&#x000b0;C. The test substance was prepared by dilution with an appropriate volume of complete growth medium (DMEM) supplemented with 10% foetal bovine serum (FBS) to obtain the highest working concentration of 100&#x02009;&#x000b5;g/ml (weight/volume). Procedures were performed aseptically.</p><p id="Par28">The test substance was tested in triplicate at concentrations of 3.125, 6.25, 12.5, 25, 50 and 100&#x02009;&#x000b5;g/ml. Growth medium from each well of a 96-well plate containing healthy culture was replaced with 200&#x02009;&#x000b5;l of the test substance and controls respectively. The cultures were then incubated for 24&#x02009;hours at 37&#x02009;&#x000b0;C in a humidified atmosphere of 5% carbon dioxide and 95% air.</p></sec><sec id="Sec18"><title><italic>In vitro</italic> cytotoxicity assay</title><p id="Par29">Cells were plated in 96-well microplates and cultured for 24&#x02009;h. The test compounds were dissolved in DMSO and added at different concentrations (100, 50, 25, 12.5, 6.25, 3.13&#x02009;&#x000b5;g/ml) to the plate in triplicate. The cytotoxicities against K-562 and H1299 cell lines were measured using a colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)&#x02212;2,5-diphenyltetrazolium bromide) assay. Exponentially growing cells were harvested and suspended in DMEM, and a 100&#x02009;&#x000b5;l cell suspension was added to a 96-well plate. After 24&#x02009;h incubation at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub>, the cells were treated with varying concentrations of the test compounds (100&#x02009;&#x000b5;l). The medium was removed, and cells in each well were incubated with PBS containing 1&#x02009;mg/ml MTT for 24&#x02009;h at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub>. DMSO (100&#x02009;&#x000b5;l) was added to each well to dissolve the insoluble formazan crystal, and plates were incubated for 4&#x02009;h at 37&#x02009;&#x000b0;C for complete solubilization of formazan. The level of coloured formazan derivative was analysed on a microplate reader using the results at wavelengths of 570&#x02009;nm and 630&#x02009;nm as references<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. The percent viability of cells was calculated using the following equation:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \% \mathrm{viability}=\,\frac{{\rm{Absorbance}}\,{\rm{of}}\,{\rm{treated}}\,{\rm{cells}}}{{\rm{Absorbance}}\,{\rm{of}}\,{\rm{cells}}\,{\rm{in}}\,{\rm{solvent}}}\times 100$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mo>%</mml:mo><mml:mi>viability</mml:mi><mml:mo>=</mml:mo><mml:mspace width=".25em"/><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Absorbance</mml:mi><mml:mspace width=".25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width=".25em"/><mml:mi mathvariant="normal">treated</mml:mi><mml:mspace width=".25em"/><mml:mi mathvariant="normal">cells</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Absorbance</mml:mi><mml:mspace width=".25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width=".25em"/><mml:mi mathvariant="normal">cells</mml:mi><mml:mspace width=".25em"/><mml:mi mathvariant="normal">in</mml:mi><mml:mspace width=".25em"/><mml:mi mathvariant="normal">solvent</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:math><graphic xlink:href="41598_2018_22485_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par30">Percent viability was plotted versus compound concentration, and IC<sub>50</sub> values at which the compound showed 50% inhibition of tumour cell proliferation were calculated using Microsoft Excel. The compound was tested at each concentration in triplicate.</p></sec><sec id="Sec19"><title>HIV-1 protease fluorogenic assay</title><p id="Par31">The HIV-1 Protease Inhibitor Screening Kit (Fluorometric) from Biovision Incorporated (Milpitas, CA, USA) was used to measure the inhibitory effect of each sample on HIV-1 protease activity. Pepstatin A (1&#x02009;mM) was used as a known standard for HIV-1 protease inhibition, and 1% DMSO was used as a solvent control. The assay was performed according to the manufacturer&#x02019;s instructions. Briefly, each sample (1&#x02009;mg/ml) was incubated with HIV-1 protease enzyme at room temperature for 15&#x02009;minutes. Then, the HIV-1 protease fluorescent substrate was added. The fluorescence (excitation/emission&#x02009;=&#x02009;330/450&#x02009;nm) in kinetic mode over a period of 90&#x02009;minutes at 37&#x02009;&#x000b0;C was determined using a PerkinElmer EnSpire plate reader.</p></sec></sec><sec id="Sec20"><title>Statistical analysis</title><p id="Par32">One-way ANOVA at 95% confidence level was used for statistical analysis followed by Dunnett&#x02019;s test in relation to control and standard.</p></sec><sec id="Sec21"><title>Molecular docking</title><p id="Par33">The structure of wild-type HIV-1 protease (PDB ID: 3OXC) was downloaded from the protein databank for molecular docking. The protein model was prepared by removing all non-standard residues that included antiviral drug saquinavir, sulfate ion and formic acid in their structure. Water molecules were removed from the structure and hydrogen atoms added using AutoDockTools-1.5.6 prior to conversion of the file format to PDBQT for docking analysis. A grid box with dimensions of 50&#x02009;&#x000d7;&#x02009;40&#x02009;&#x000d7;&#x02009;40 A<sup>3</sup> was generated with HIV-1 protease as the centroid using AutoDockTools-1.5.6. Vanicoside, pepstatin, and polygonuminss were docked in the HIV-1 protease using AutoDockVina 1.1.2<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Docking of the molecules was repeated in three independent runs. Structures were visualized and hydrogen bond interactions were further analysed using UCSF Chimera version 1.11<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>.</p></sec></sec><sec id="Sec22" sec-type="conclusion"><title>Conclusion</title><p id="Par34">Polygonumins A, a new compound isolated from <italic>P</italic>. <italic>minus</italic>, showed promising anticancer and HIV protease inhibition activities. This compound has been filed for a Malaysian patent (PI 2014700594). In summary, our investigation provided promising results supporting the potential use of <italic>P</italic>. <italic>minus</italic> in the treatment of cancers such as leukaemia and colorectal and breast cancer and as an anti-HIV agent. Hopefully, these leads can be taken up for the further development of anticancer and anti-HIV drugs.</p></sec></body><back><fn-group><fn><p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The study was funded by Universiti Kebangsaan Malaysia grants (UKM-AP-BPB-14&#x02013;2009) awarded to Normah Mohd Noor and Research University Grants from Universiti Kebangsaan Malaysia (UKM-GUP-2013&#x02013;028 and DLP 2013-024) awarded to Syarul Nataqain Baharum. We acknowledge Chulalongkorn University for the Visiting Lecturer Fellowship 2017 awarded to Syarul Nataqain Baharum. We thank Emelda R. Rohani for her significant contribution to the isolation of polygonumins A. We also acknowledge Bimo A. Tejo for his contribution in molecular docking analysis. The HIV-1 test assay was funded by the 90<sup>th</sup> Anniversary of Chulalongkorn University, Rachadapisek Sompote Fund awarded to Siriporn Chuchawankul and Chanin Sillapachaiyaporn. We also acknowledge the Centre for Research and Instrumentation Management (CRIM), UKM for Research Instrumentation Development Grants awarded in 2010 and 2013 (PIP-CRIM).</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>S.N.B. and N.M.N. conceived and designed the whole experiments; R.A., I.S., M.T., C.F.L. and C.S. performed the experiments and analysed the data; S.N.B., N.M.N. and S.C. contributed reagents/materials/analysis tools; F.I. and N.F.R. performed the cytotoxicity test; R.A., I.S., C.F.L. C.S, S.C., T.S., T.T. and S.N.B. wrote and edited the paper. All authors reviewed the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing Interests</title><p id="Par35">The authors declare no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poonthananiwatkul</surname><given-names>B</given-names></name><name><surname>Lim</surname><given-names>RHM</given-names></name><name><surname>Howard</surname><given-names>RL</given-names></name><name><surname>Pibanpaknitee</surname><given-names>P</given-names></name><name><surname>Williamson</surname><given-names>EM</given-names></name></person-group><article-title>Traditional medicine use by cancer patients in Thailand</article-title><source>Journal of Ethnopharmacology</source><year>2015</year><volume>168</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2015.03.057</pub-id><?supplied-pmid 25847624?><pub-id pub-id-type="pmid">25847624</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X-Z</given-names></name><name><surname>Zhang</surname><given-names>S-N</given-names></name><name><surname>Liu</surname><given-names>S-M</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name></person-group><article-title>Recent advances in herbal medicines treating Parkinson&#x02019;s disease</article-title><source>Fitoterapia</source><year>2013</year><volume>84</volume><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2012.12.009</pub-id><?supplied-pmid 23266574?><pub-id pub-id-type="pmid">23266574</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Hassan, W. W. Healing Herbs of Malaysia. <italic>Federal Land Development Authority (FELDA)</italic>, <italic>Kuala Lumpur</italic> (2007).</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>M</given-names></name></person-group><article-title>Australian kesom oil - A new essential oil for the flavour and fragrance industry</article-title><source>Agro Food Industry Hi-Tech</source><year>1996</year><volume>7</volume><fpage>26</fpage><lpage>28</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazawa</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>N</given-names></name></person-group><article-title>Components of the essential oil from sprouts of Polygonum hydropiper L. (&#x02018;Benitade&#x02019;)</article-title><source>Flavour and Fragrance Journal</source><year>2007</year><volume>22</volume><fpage>188</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1002/ffj.1779</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Vimala, S., Adenan, M. I., Ahmad, A. R. &#x00026; Shahdan, R. <italic>Nature&#x02019;s choice to wellness</italic>, <italic>antioxidant vegetables/ulam</italic>. (Forest Research Institute Malaysia, 2003).</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Burkill, H., Vol. 2 (Kuala Lumpur: Ministry of Agriculture &#x00026; Cooperatives, 1966).</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassim</surname><given-names>N</given-names></name><etal/></person-group><article-title>Antioxidant and Antibacterial Assays on Polygonum minus Extracts: Different ExtractionMethods</article-title><source>International Journal of Chemical Engineering</source><year>2015</year><volume>2015</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1155/2015/826709</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>A</given-names></name><etal/></person-group><article-title>Anti-inflammatory effects of Polygonum minus (Huds) extract (LineminusTM) in <italic>in-vitro</italic> enzyme assays and carrageenan induced paw edema</article-title><source>BMC Complementary and Alternative Medicine</source><year>2014</year><volume>14</volume><fpage>355</fpage><pub-id pub-id-type="doi">10.1186/1472-6882-14-355</pub-id><?supplied-pmid 25252832?><pub-id pub-id-type="pmid">25252832</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Antiviral and Cytotoxic Activities of Some Plants Used in Malaysian Indigenous Medicine</article-title><source>Pertanika Journal of Tropical Agricultural Science</source><year>1996</year><volume>19</volume><issue>2/3</issue><fpage>129</fpage><lpage>136</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qader</surname><given-names>S</given-names></name><name><surname>Abdulla</surname><given-names>M</given-names></name><name><surname>Chua</surname><given-names>L</given-names></name><name><surname>Sirat</surname><given-names>H</given-names></name><name><surname>Hamdan</surname><given-names>S</given-names></name></person-group><article-title>Pharmacological mechanisms underlying gastroprotective activities of the fractions obtained from Polygonum minus in sprague dawley rats</article-title><source>Int J Mol Sci</source><year>2012</year><volume>13</volume><fpage>1481</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.3390/ijms13021481</pub-id><?supplied-pmid 22408403?><pub-id pub-id-type="pmid">22408403</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Azlim Almey, A. <italic>et al</italic>. Total phenolic content and primary antioxidant activity of methanolic and ethanolic extracts of aromatic plants&#x02019; leaves. <italic>International Food Research Journal</italic><bold>17</bold> (2010).</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Huda-Faujan, N., Noriham, A., Norrakiah, A. &#x00026; Babji, A. Antioxidant activity of plants methanolic extracts containing phenolic compounds. <italic>African Journal of Biotechnology</italic><bold>8</bold> (2009).</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Maizura, M., Aminah, A. &#x00026; Aida, W. M. W. Total phenolic content and antioxidant activity of kesum (Polygonum minus), ginger (Zingiber officinale) and turmeric (Curcuma longa) extract. <italic>International Food Research Journal</italic><bold>18</bold> (2011).</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baharum</surname><given-names>SN</given-names></name><name><surname>Bunawan</surname><given-names>H</given-names></name><name><surname>Ghani</surname><given-names>MA</given-names></name><name><surname>Mustapha</surname><given-names>WA</given-names></name><name><surname>Noor</surname><given-names>NM</given-names></name></person-group><article-title>Analysis of the chemical composition of the essential oil of polygonum minus huds. Using two-dimensional gas chromatography-time-of-flight mass spectrometry (GC-TOF MS)</article-title><source>Molecules</source><year>2010</year><volume>15</volume><fpage>7006</fpage><lpage>7015</lpage><pub-id pub-id-type="doi">10.3390/molecules15107006</pub-id><?supplied-pmid 20944520?><pub-id pub-id-type="pmid">20944520</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R</given-names></name><etal/></person-group><article-title>Volatile Profiling of Aromatic Traditional Medicinal Plant, Polygonum minus in Different Tissues and Its Biological Activities</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>19220</fpage><lpage>19242</lpage><pub-id pub-id-type="doi">10.3390/molecules191119220</pub-id><?supplied-pmid 25420073?><pub-id pub-id-type="pmid">25420073</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R</given-names></name><name><surname>Bunawan</surname><given-names>H</given-names></name><name><surname>Normah</surname><given-names>MN</given-names></name><name><surname>Baharum</surname><given-names>SN</given-names></name></person-group><article-title>Chemical composition in different tissues of Polygonum minus by using GC X GC-TOF MS and direct discrimination by multivariate analysis of fourier transform infrared spectroscopy data</article-title><source>International Journal of Pharmacognosy and Phytochemical Research</source><year>2016</year><volume>8</volume><fpage>1986</fpage><lpage>1992</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>ML</given-names></name><name><surname>Sneden</surname><given-names>AT</given-names></name></person-group><article-title>Vanicosides A and B, Protein Kinase C Inhibitors from Polygonum pensylvanicum</article-title><source>Journal of Natural Products</source><year>1994</year><volume>57</volume><fpage>236</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1021/np50104a007</pub-id><?supplied-pmid 8176400?><pub-id pub-id-type="pmid">8176400</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordell</surname><given-names>GA</given-names></name><name><surname>Beecher</surname><given-names>CWW</given-names></name><name><surname>Pezzuto</surname><given-names>JM</given-names></name></person-group><article-title>Can ethnopharmacology contribute to the development of new anticancer drugs?</article-title><source>Journal of Ethnopharmacology</source><year>1991</year><volume>32</volume><fpage>117</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/0378-8741(91)90110-Y</pub-id><?supplied-pmid 1881151?><pub-id pub-id-type="pmid">1881151</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Boik, J. (Oregon Medical Press, Princeton, MN, USA, 2001).</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efferth</surname><given-names>T</given-names></name><name><surname>Miyachi</surname><given-names>H</given-names></name><name><surname>Bartsch</surname><given-names>H</given-names></name></person-group><article-title>Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy</article-title><source>Cancer Genomics and Proteomics</source><year>2007</year><volume>4</volume><fpage>81</fpage><lpage>91</lpage><?supplied-pmid 17804870?><pub-id pub-id-type="pmid">17804870</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzoyem</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Cytotoxicity and antimicrobial activity of the methanol extract and compounds from Polygonum limbatum</article-title><source>Planta Medica</source><year>2012</year><volume>78</volume><fpage>787</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1298431</pub-id><?supplied-pmid 22495442?><pub-id pub-id-type="pmid">22495442</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Lin, Y.-S. <italic>et al</italic>. <italic>In vitro</italic> and <italic>in vivo</italic> anticancer activity of a synthetic glycolipid as TLR4 activator. <italic>Journal of Biological Chemistry</italic>, 10.1074/jbc.M111.285171 (2011).</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Syntheses and biological activities of daunorubicin analogs with uncommon sugars</article-title><source>Bioorganic &#x00026; Medicinal Chemistry</source><year>2005</year><volume>13</volume><fpage>6381</fpage><lpage>6387</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2005.06.053</pub-id><pub-id pub-id-type="pmid">16055335</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cingi</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Choice and standardization of test protocols in cytotoxicology: A multicentre approach</article-title><source>Toxicology in Vitro</source><year>1991</year><volume>5</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/0887-2333(91)90031-8</pub-id><?supplied-pmid 20732005?><pub-id pub-id-type="pmid">20732005</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>RJ</given-names></name><name><surname>Rispat</surname><given-names>GW</given-names></name><name><surname>Chevalier</surname><given-names>G</given-names></name><name><surname>Massingham</surname><given-names>A</given-names></name><name><surname>Can</surname><given-names>R</given-names></name></person-group><article-title>the <italic>in vivo</italic> maximum tolerated dose be predicted using <italic>in vitro</italic> techniques? A working hypothesis</article-title><source>ATLA</source><year>1991</year><volume>19</volume><fpage>393</fpage><lpage>402</lpage></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Borges de Melo, E., Gomes, A. S. &#x00026; Carvalho, I. &#x003b1;- and &#x003b2;-Glucosidase inhibitors: chemical structure and biological activity. <italic>Tetrahedron</italic><bold>62</bold>, 10277&#x02013;10302, 10.1016/j.tet.2006.08.055 (2006).</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Anti-cholinergic, cytotoxic and anti-HIV-1 activities of sesquiterpenes and a flavonoid glycoside from the aerial parts of Polygonum viscosum</article-title><source>Pharmaceutical Biology</source><year>2004</year><volume>42</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1080/13880200490504943</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Anti-HIV activities of the compounds isolated from polygonum cuspidatum and polygonum multiflorum</article-title><source>Planta Medica</source><year>2010</year><volume>76</volume><fpage>889</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1055/s-0029-1240796</pub-id><?supplied-pmid 20112182?><pub-id pub-id-type="pmid">20112182</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Highly potent anti-HIV-1 activity isolated from fermented Polygonum tinctorium Aiton</article-title><source>Antiviral Research</source><year>2005</year><volume>66</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.02.003</pub-id><?supplied-pmid 15911029?><pub-id pub-id-type="pmid">15911029</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>HIV-1 integrase inhibitory phenylpropanoid glycosides from Clerodendron trichotomum</article-title><source>Archives of pharmacal research</source><year>2001</year><volume>24</volume><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/BF02975093</pub-id><?supplied-pmid 11534758?><pub-id pub-id-type="pmid">11534758</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qader</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Antioxidant, total phenolic content and cytotoxicity evaluation of selected Malaysian plants</article-title><source>Molecules</source><year>2011</year><volume>16</volume><fpage>3433</fpage><lpage>3443</lpage><pub-id pub-id-type="doi">10.3390/molecules16043433</pub-id><?supplied-pmid 21512451?><pub-id pub-id-type="pmid">21512451</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>P</given-names></name><name><surname>Terrier</surname><given-names>L</given-names></name><name><surname>Hay</surname><given-names>AE</given-names></name><name><surname>Marston</surname><given-names>A</given-names></name><name><surname>Hostettmann</surname><given-names>K</given-names></name></person-group><article-title>Antioxidant and enzyme inhibition activities and chemical profiles of Polygonum sachalinensis F.Schmidt ex Maxim (Polygonaceae)</article-title><source>Fitoterapia</source><year>2010</year><volume>81</volume><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2009.08.019</pub-id><?supplied-pmid 19698767?><pub-id pub-id-type="pmid">19698767</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Gaulejac</surname><given-names>NS-C</given-names></name><name><surname>Glories</surname><given-names>Y</given-names></name><name><surname>Vivas</surname><given-names>N</given-names></name></person-group><article-title>Free radical scavenging effect of anthocyanins in red wines</article-title><source>Food Res Int.</source><year>1999</year><volume>32</volume><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/S0963-9969(99)00093-9</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atta ur</surname><given-names>R</given-names></name><name><surname>Choudhary</surname><given-names>MI</given-names></name></person-group><article-title>Bioactive natural products as a potential source of new pharmacophores. A theory of memory</article-title><source>Pure and Applied Chemistry</source><year>2001</year><volume>73</volume><fpage>555</fpage><lpage>560</lpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papandreou</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Effect of a polyphenol-rich wild blueberry extract on cognitive performance of mice, brain antioxidant markers and acetylcholinesterase activity</article-title><source>Behavioural Brain Research</source><year>2009</year><volume>198</volume><fpage>352</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2008.11.013</pub-id><?supplied-pmid 19056430?><pub-id pub-id-type="pmid">19056430</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapewangolo</surname><given-names>P</given-names></name><name><surname>Tawha</surname><given-names>T</given-names></name><name><surname>Nawinda</surname><given-names>T</given-names></name><name><surname>Knott</surname><given-names>M</given-names></name><name><surname>Hans</surname><given-names>R</given-names></name></person-group><article-title>Sceletium tortuosum demonstrates <italic>in vitro</italic> anti-HIV and free radical scavenging activity</article-title><source>South African Journal of Botany</source><year>2016</year><volume>106</volume><fpage>140</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.sajb.2016.06.009</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thayil</surname><given-names>SM</given-names></name><name><surname>Thyagarajan</surname><given-names>SP</given-names></name></person-group><article-title>PA-9: A Flavonoid Extracted from Plectranthus amboinicus Inhibits HIV-1 Protease</article-title><source>International Journal of Pharmacognosy and Phytochemical Research</source><year>2016</year><volume>8</volume><fpage>1020</fpage><lpage>1024</lpage></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CR</given-names></name><etal/></person-group><article-title>First report on isolation of methyl gallate with antioxidant, anti-HIV-1 and HIV-1 enzyme inhibitory activities from a mushroom (Pholiota adiposa)</article-title><source>Environ Toxicol Pharmacol</source><year>2014</year><volume>37</volume><fpage>626</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.etap.2014.01.023</pub-id><?supplied-pmid 24572641?><pub-id pub-id-type="pmid">24572641</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzaghi-Asl</surname><given-names>N</given-names></name><name><surname>Sepehri</surname><given-names>S</given-names></name><name><surname>Ebadi</surname><given-names>A</given-names></name><name><surname>Miri</surname><given-names>R</given-names></name><name><surname>Shahabipour</surname><given-names>S</given-names></name></person-group><article-title>Effect of Biomolecular Conformation on Docking Simulation: A Case Study on a Potent HIV-1 Protease Inhibitor</article-title><source>Iranian Journal of Pharmaceutical Research: IJPR</source><year>2015</year><volume>14</volume><fpage>785</fpage><lpage>802</lpage><?supplied-pmid 26330867?><pub-id pub-id-type="pmid">26330867</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunawan</surname><given-names>H</given-names></name><name><surname>Choong</surname><given-names>C</given-names></name><name><surname>Md-Zain</surname><given-names>B</given-names></name><name><surname>Baharum</surname><given-names>S</given-names></name><name><surname>Noor</surname><given-names>N</given-names></name></person-group><article-title>Molecular systematics of Polygonum minus Huds. based on ITS sequences</article-title><source>Int J Mol Sci</source><year>2011</year><volume>12</volume><fpage>7626</fpage><lpage>7634</lpage><pub-id pub-id-type="doi">10.3390/ijms12117626</pub-id><?supplied-pmid 22174621?><pub-id pub-id-type="pmid">22174621</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellman</surname><given-names>GL</given-names></name><name><surname>Courtney</surname><given-names>KD</given-names></name></person-group><article-title>Andres jr, V. &#x00026; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity</article-title><source>Biochemical Pharmacology</source><year>1961</year><volume>7</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(61)90145-9</pub-id><?supplied-pmid 13726518?><pub-id pub-id-type="pmid">13726518</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Oyaizu, M. Studies on products of browning reaction prepared from glucoseamine. <italic>Japanese JNutr</italic><bold>44</bold> (1986).</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootton-Beard</surname><given-names>PC</given-names></name><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>L</given-names></name></person-group><article-title>Stability of the total antioxidant capacity and total polyphenol content of 23 commercially available vegetable juices before and after <italic>in vitro</italic> digestion measured by FRAP, DPPH, ABTS and Folin&#x02013;Ciocalteu methods</article-title><source>Food Research International</source><year>2011</year><volume>44</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.foodres.2010.10.033</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Matsuki</surname><given-names>N</given-names></name></person-group><article-title>Measurement of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate dehydrogenase release using MTT</article-title><source>Neuroscience Research</source><year>2000</year><volume>38</volume><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/S0168-0102(00)00188-7</pub-id><?supplied-pmid 11164558?><pub-id pub-id-type="pmid">11164558</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading</article-title><source>Journal of computational chemistry</source><year>2010</year><volume>31</volume><fpage>455</fpage><lpage>461</lpage><?supplied-pmid 19499576?><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><etal/></person-group><article-title>UCSF Chimera&#x02013;a visualization system for exploratory research and analysis</article-title><source>J Comput Chem</source><year>2004</year><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><?supplied-pmid 15264254?><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takasaki</surname><given-names>M</given-names></name><name><surname>Konoshima</surname><given-names>T</given-names></name><name><surname>Kuroki</surname><given-names>S</given-names></name><name><surname>Tokuda</surname><given-names>H</given-names></name><name><surname>Nishino</surname><given-names>H</given-names></name></person-group><article-title>Cancer chemopreventive activity of phenylpropanoid esters of sucrose, vanicoside B and lapathoside A, from Polygonum lapathifolium</article-title><source>Cancer letters</source><year>2001</year><volume>173</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(01)00670-X</pub-id><?supplied-pmid 11597787?><pub-id pub-id-type="pmid">11597787</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiem</surname><given-names>PV</given-names></name><etal/></person-group><article-title>New phenylpropanoid esters of sucrose from Polygonum hydropiper and their antioxidant activity</article-title><source>Archives of pharmacal research</source><year>2008</year><volume>31</volume><fpage>1477</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1007/s12272-001-2133-y</pub-id><?supplied-pmid 19023545?><pub-id pub-id-type="pmid">19023545</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>beta-Glucosidase inhibitory activities of phenylpropanoid glycosides, vanicoside A and B from Polygonum sachalinense rhizome</article-title><source>Fitoterapia</source><year>2006</year><volume>77</volume><fpage>456</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2006.05.008</pub-id><?supplied-pmid 16828242?><pub-id pub-id-type="pmid">16828242</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumagai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Antimicrobial substances from rhizomes of the giant knotweed Polygonum sachalinense against the fish pathogen Photobacterium damselae subsp. piscicida</article-title><source>Zeitschrift fur Naturforschung. C, Journal of biosciences</source><year>2005</year><volume>60</volume><fpage>39</fpage><lpage>44</lpage><?supplied-pmid 15787242?><pub-id pub-id-type="pmid">15787242</pub-id></element-citation></ref></ref-list></back></article>